Pharmaceutical

Biocon and Handok link to commercialise Liraglutide in South Korea

Biocon has entered an exclusive licence and supply agreement with Handok to commercialise synthetic Liraglutide in South Korea.

May 25, 2024 - 04:00
Biocon and Handok link to commercialise Liraglutide in South Korea
Biocon has entered an exclusive licence and supply agreement with Handok to commercialise synthetic Liraglutide in South Korea.
Read the original article

Tags:

Previous Article

EC approves Celltrion’s Omlyclo for allergic conditions

Next Article

Magazine: Lula’s progress plan for Brazil: a year on

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Cipla and Glenmark initiate recall of certain products in the US

Cipla and Glenmark initiate recall of certain products ...

May 7, 2024

How to identify and remove CNS assessment errors to avoid jeopardising a trial

How to identify and remove CNS assessment errors to avo...

May 21, 2024

STAT+: EU releases proposed pharma overhaul, cutting period of market exclusivity

STAT+: EU releases proposed pharma overhaul, cutting pe...

Apr 27, 2023